Ganga Pharmaceuticals Limited members approved the re-appointment of Bharat Brijmohan Sharma as Managing Director for a further period of three years. The appointment is effective from April 1, 2026.

The decision was taken at the company's 37th Annual General Meeting held on September 26, 2026. The meeting commenced at 4:30 pm and concluded at 5:00 pm. Sharma will serve for the new term without being liable to retire by rotation.

Governance and Disclosure Details

The company filed an intimation with BSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that Sharma is not debarred from holding the office of Director by any SEBI order or authority.

Sharma brings over 35 years of experience in the business and pharmaceutical industry to his role. The disclosure also notes a familial relationship within the board structure.

Key Personnel Information

Bharat Brijmohan Sharma holds Director Identification Number 00077026. The annexure to the filing highlights that he is the spouse of Srijna Sharma, who serves as the Whole-time Director of the company. This relationship is disclosed in compliance with regulatory requirements regarding relationships between directors.

The information has been made available on the company's official website for public reference.

Ganga Pharmaceuticals Limited concluded its 37th Annual General Meeting (AGM) on September 26, 2026, with all three proposed resolutions passing unanimously. The meeting, held at the registered office in Virar, Maharashtra, saw members approve the adoption of financial statements, director re-appointments, and other agenda items without any votes cast against them.

The proceedings were conducted in compliance with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Sanjay Kulkarni, Chairman of the Board, presided over the meeting, which commenced at 4:30 pm and ended at 4:55 pm. The Scrutinizer’s report confirmed that 100% of the valid votes cast were in favor of each resolution.

Attendance and Quorum

A total of 10 members were personally present at the meeting. After verifying that the requisite quorum was met, the Chairman called the meeting to order. The Register of Directors' Shareholding was kept open for inspection throughout the duration of the AGM.

Directors Present

Other key personnel present included Mr. Gaurav Thakur, representative of M/s. Gaurav Thakur & Co (Scrutinizer), Mr. Pradeep Banka from Banka & Bank (Statutory Auditors), Mr. Dhirendra Maurya from M/s. D Maurya & Associates (Secretarial Auditor), and Mr. Anagh Sharma, Chief Financial Officer.

Voting Results and Resolutions Passed

In accordance with Section 108 of the Companies Act, 2013, the company offered a remote e-voting facility to enable members to cast their votes electronically. The remote voting window opened on September 23, 2026, at 9:00 am and closed on September 25, 2026, at 5:00 pm. The final poll results, including e-voting outcomes, were announced by the Scrutinizer, CMA Gaurav Thakur.

The following three ordinary resolutions were passed with requisite majority:

1. Adoption of Financial Statements: To receive, consider and adopt the Audited Financial Statements for the financial year ended March 31, 2026, including the Balance Sheet and Statement of Profit and Loss.
2. Re-appointment of Director: To re-appoint Mr. Sanjay Kulkarni (DIN: 00065190) as a Director retiring by rotation.
3. Re-appointment of MD: To re-appoint Mr. Bharat Brijmohan Sharma as Managing Director & Chief Executive Officer (CEO).

Detailed Voting Breakdown

The voting results indicate a complete consensus among shareholders who participated in the voting process. Promoters and public non-institutional shareholders voted exclusively in favor of all resolutions.

Note: Total shares outstanding were 5,911,500. Votes polled represented approximately 54.16% of total shares.

What the Numbers Show

The voting data reveals a high concentration of promoter influence alongside strong public support among participating shareholders. Promoters and their group held 3,009,550 shares, casting 3,009,550 votes (100% of their holding). Public non-institutional shareholders held 2,901,950 shares but only 192,110 votes were polled from this category, representing just 6.62% of their holding. Despite the low participation rate from the public category, every single vote cast was in favor, resulting in a 100% approval rating across all three resolutions. This suggests either strong alignment between management and participating minority shareholders or limited dissenting interest among those who chose to vote.